EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Augmented Enteral Protein During Critical Illness

Matthew J Summers, Lee-Anne S Chapple, Amalia Karahalios, Rinaldo Bellomo, Marianne J Chapman, Suzie Ferrie, Mark E Finnis, Craig French, Sally Hurford, Nima Kakho, Matthew J Maiden, Stephanie N O'Connor und 9 weitere

JAMA · 22.07.2025 · 334 (4) · 319

DOI: 10.1001/jama.2025.9110 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 22.07.2025. Verfasst von Matthew J Summers und 20 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Acute Care Medicine, The University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Critical Illness, Dietary Proteins, Enteral Nutrition, Food, Formulated. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Guidelines recommend augmenting enteral protein during critical illness, but the impact on patient outcomes is uncertain.

Objective

To determine whether augmenting enteral protein increases days alive and free from hospitalization. Design, Setting, and Participants This cluster randomized, crossover, open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23, 2022, to August 23, 2023, with final follow-up on November 21, 2023.

Intervention

Two isocaloric enteral formulae were compared: augmented protein (100 g protein/L) vs usual protein (63 g protein/L). ICUs used formulae sequentially for 3 months over a 12-month period; 4 ICUs commenced with augmented protein and 4 commenced with usual protein. Main Outcomes and Measures The primary outcome was the number of days free of admittance to the index hospital and alive at day 90. Secondary outcomes included days free of the index hospital at day 90 in survivors; alive at day 90; durations of invasive ventilation, ICU, and hospital admission; incidences of tracheostomy insertion and new kidney replacement therapy; and hospital discharge destination.

Results

A total of 3397 patients were included (median [IQR] age, 61 (48-71) years; 2157 [64%] male). The median (IQR) number of days free of the index hospital and alive at day 90 was 62 (0-77) days in the augmented protein group and 64 (0-77) days in the usual protein group, with an adjusted-for-period between-group median difference of −1.97 (95% CI, −7.24 to 3.30) days ( P = .46). At day 90, a total of 1221 of 1681 patients (72.6%) were alive in the augmented protein group and 1269 of 1716 (74.0%) were alive in the usual protein group (risk ratio, 0.99 [95% CI, 0.95-1.03]). Between-group differences for secondary outcomes included the following: difference in median days free of hospital in survivors, 0.01 (95% CI, −1.94 to 1.96) days; difference in mean duration of invasive ventilation, 6.8 (95% CI, −3.0 to 16.5) hours; cause-specific hazard ratios for durations of ICU admission (time to live ICU discharge), 0.93 (95% CI, 0.88-1.00) and hospital admission (time to live hospital discharge), 0.96 (95% CI, 0.90-1.02); and risk ratio for tracheostomy, 1.15 (95% CI, 0.66-2.01) and new kidney replacement therapy, 0.97 (95% CI, 0.81-1.16). Discharge destinations were similar. Conclusions and Relevance Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90. Trial Registration ANZCTR Identifier: ACTRN12621001484831

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Critical IllnessDietary ProteinsEnteral NutritionFood, FormulatedAgedFemaleHumansMaleMiddle AgedAustraliaCross-Over StudiesIntensive Care UnitsLength of StayNew ZealandPatient DischargeRenal Replacement TherapyRespiration, ArtificialTracheostomyHospital Mortality

Substanzen

Dietary Proteins

Autor:innen und Institutionen

  • Discipline of Acute Care Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
  • Intensive Care Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Centre for Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.
  • Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia.
  • Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
  • Methods and Implementation Support for Clinical and Health research (MISCH) Hub, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

Zitieren

APA

Summers, M. J., Chapple, L. S., Karahalios, A., Bellomo, R., Chapman, M. J., Ferrie, S., Finnis, M. E., French, C., Hurford, S., Kakho, N., Maiden, M. J., O'Connor, S. N., Peake, S. L., Presneill, J. J., Ridley, E. J., Tran-Duy, A., Williams, P. J., Young, P. J., Zaloumis, S., …, & TARGET Protein Investigators and for the Australian and New Zealand Intensive Care Society Clinical Trials Group (2025). Augmented Enteral Protein During Critical Illness. JAMA, 334(4), 319. https://doi.org/10.1001/jama.2025.9110

Vancouver

Summers MJ, Chapple LS, Karahalios A, Bellomo R, Chapman MJ, Ferrie S, et al. Augmented Enteral Protein During Critical Illness. JAMA. 2025;334(4):319. doi:10.1001/jama.2025.9110

BibTeX
@article{Summers2025,
  author = {Summers, Matthew J and Chapple, Lee-Anne S and Karahalios, Amalia and Bellomo, Rinaldo and Chapman, Marianne J and Ferrie, Suzie and Finnis, Mark E and French, Craig and Hurford, Sally and Kakho, Nima and Maiden, Matthew J and O'Connor, Stephanie N and Peake, Sandra L and Presneill, Jeffrey J and Ridley, Emma J and Tran-Duy, An and Williams, Patricia J and Young, Paul J and Zaloumis, Sophie and Deane, Adam M and TARGET Protein Investigators and for the Australian and New Zealand Intensive Care Society Clinical Trials Group, TARGET Protein Investigators and for the Australian and New Zealand Intensive Care Society Clinical Trials Group},
  title = {Augmented Enteral Protein During Critical Illness},
  journal = {JAMA},
  year = {2025},
  volume = {334},
  number = {4},
  pages = {319},
  doi = {10.1001/jama.2025.9110}
}
Kostenlos starten →